“…2,21 Still, none of the clinically used inhibitors 4-7 (or other structurally related investigational agents) 21 proved to be effective when administered topically in reducing elevated IOP, and thus, for a long period, it was considered that sulfonamide CAIs cannot be administered via topical route. 22 In a classical study, Maren's group then showed that this is principally due to the unappropriate physicochemical properties of the existing CAIs available at that moment, and put the basis for the discovery of the topically acting sulfonamides: the first such drug, dorzolamide (8), 29 entered in clinics in 1995, and the second one (structurally related to dorzolamide)-brinzolamide (9) 30 entered in clinics in 1999. Thus, in addition to the systemically acting inhibitors 4-7, the clinical antiglaucoma armamentarium comprises these two new drugs, which show much less side effects as compared to the first drugs mentioned above, but which also basically inhibit all the physiologically relevant CA isozymes (Table II).…”